Ziopharm Oncology Inc. (NASDAQ:ZIOP) traded down 3.6% during mid-day trading on Thursday . The stock traded as low as $4.80 and last traded at $4.84, with a volume of 751,125 shares traded. The stock had previously closed at $5.02.

Several equities research analysts have recently issued reports on the stock. Vetr cut shares of Ziopharm Oncology from a “strong-buy” rating to a “buy” rating and set a $9.76 price objective for the company. in a research report on Monday, April 18th. Raymond James Financial Inc. initiated coverage on shares of Ziopharm Oncology in a research report on Thursday, June 2nd. They issued a “market perform” rating for the company. Wells Fargo & Co. reissued a “sell” rating and issued a $6.50 price target on shares of Ziopharm Oncology in a research report on Thursday, May 12th. Zacks Investment Research raised shares of Ziopharm Oncology from a “sell” rating to a “hold” rating in a research report on Wednesday, May 11th. Finally, Mizuho boosted their price target on shares of Ziopharm Oncology from $6.00 to $7.00 and gave the company a “neutral” rating in a research report on Wednesday, May 11th. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating, two have issued a buy rating and one has issued a strong buy rating to the stock. Ziopharm Oncology currently has an average rating of “Hold” and an average price target of $9.55.

The company’s 50-day moving average price is $5.61 and its 200-day moving average price is $6.79. The firm’s market cap is $627.64 million.

Ziopharm Oncology (NASDAQ:ZIOP) last released its quarterly earnings data on Tuesday, May 10th. The biotechnology company reported ($0.09) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.08) by $0.01. The firm had revenue of $1.97 million for the quarter, compared to the consensus estimate of $1.89 million. The firm’s quarterly revenue was up 623.9% on a year-over-year basis. During the same period in the prior year, the firm earned ($0.69) earnings per share. Equities research analysts anticipate that Ziopharm Oncology Inc. will post ($0.42) EPS for the current year.

Other large investors have added to or reduced their stakes in the company. Morgan Stanley raised its stake in Ziopharm Oncology by 5.1% in the fourth quarter. Morgan Stanley now owns 1,618,205 shares of the biotechnology company’s stock valued at $13,447,000 after buying an additional 78,583 shares during the last quarter. California State Teachers Retirement System raised its stake in Ziopharm Oncology by 1.6% in the fourth quarter. California State Teachers Retirement System now owns 212,521 shares of the biotechnology company’s stock valued at $1,766,000 after buying an additional 3,354 shares during the last quarter. Swiss National Bank raised its stake in Ziopharm Oncology by 2.2% in the fourth quarter. Swiss National Bank now owns 159,220 shares of the biotechnology company’s stock valued at $1,323,000 after buying an additional 3,500 shares during the last quarter. Finally, California Public Employees Retirement System raised its stake in Ziopharm Oncology by 567.2% in the fourth quarter. California Public Employees Retirement System now owns 307,366 shares of the biotechnology company’s stock valued at $2,554,000 after buying an additional 261,300 shares during the last quarter.

ZIOPHARM Oncology, Inc is a biopharmaceutical company. The Company is seeking to acquire, develop and commercialize, on its own or with partners, a portfolio of cancer therapies through synthetic immuno-oncology. Its clinical-stage product candidate, Ad-RTS-IL-12, is used with the oral activator veledimex.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.